- The company logs KRW89.8 billion in net sales, KRW39.0 billion in operating profit, and KRW30.9 billion in net profit, respectively up 20.9%, 62.6%, and 35.9% on-year
- All product lines such as botulinum toxin, dermal fillers, and cosmetics show steady growth; strong global performance such as additional shipments to the US expected in Q2
SEOUL, South Korea, May 8, 2025 -- Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, on May 8 posted KRW89.8 billion, KRW39.0 billion, and KRW30.9 billion for the first quarter net sales, operating profit, and net profit, respectively, based on a consolidated financial statement. With the highest-ever first-quarter earnings for the company, the figures represent increases of 20.9%, 62.6%, and 35.9%, respectively, compared with the same period of 2024.
The robust earnings growth was driven by balanced gains across all product portfolios.
The company's botulinum toxin Botulax, globally branded as Letybo, logged KRW40.7 billion in quarterly net sales, up 18.8% on-year, and made up 45% of the company's total net sales in the January-March period. The toxin's net sales showed the highest growth in the Asia-Pacific market, which includes China, Australia and Taiwan, with a 54% increase on-year.
Hyaluronic acid fillers such as THE CHAEUM and BYRYZN Skin Booster HA posted KRW34.4 billion in the first quarter net sales, up 17.7% on-year. The dermal fillers showed strong sales performance in Asia-Pacific, the Americas, and Europe as well as in South Korea.
Cosmetics achieved KRW13.2 billion in net sales for the first quarter with a notable 39.3% increase on-year. Derma cosmetics brand WELLAGE and high-end skincare brand BYRYZN BR continue to expand their customer reach by launching new products and diversifying local and global distribution channels.
"The first-quarter earnings broke records again with all products' robust growth across the world. We will strive to solidify our global position through key momentum drivers such as additional shipments to the US and entry into the Middle East in the second quarter," said a Hugel official.
Hugel's board of directors resolved on Thursday to retire 300,000 shares of treasury stock on May 15. This move follows the company's policy to ramp up shareholder return, with an aim to continuously strengthen trust in markets and increase the corporate value.
About Hugel
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. As the market leader in injectable aesthetics in South Korea, Hugel is the only South Korean company with regulatory approvals in the world's three largest botulinum toxin markets: the US, China, and Europe. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs, and dynamic industry forums. Over the past 20 years, the company has built a presence in approximately 70 countries and operates eight global subsidiaries across South Korea, the US, Australia, Canada, Taiwan, China, Hong Kong, and Singapore. Leveraging strong industry momentum, Hugel is poised for continued growth and global market expansion.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
